Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

  title={A$\beta$ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study},
  author={Kevin T Ong and Victor L. Villemagne and Alex Bahar-Fuchs and Fiona Lamb and Narelle Langdon and Ana M. Catafau and Andrew W. Stephens and John Seibyl and Ludger M. Dinkelborg and Cornelia Reininger and Barbara Putz and Beate Rohde and Colin L. Masters and Christopher C. Rowe},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  pages={431 - 436}
Background We assessed the clinical utility of β-amyloid (Aβ) imaging with 18F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time. Methods 45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow… 

Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.

Visual and SUVR Aβ PET analysis may be equivalently used to determine Aβ status for individuals with MCI participating in clinical trials, and both approaches add significant value for clinical course prognostication.

[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment

In summary, [18F]florbetaben is a highly accurate β-amyloid PET tracer that has the potential to support the clinical diagnosis of Alzheimer’s disease and other causes of cognitive decline.

Clinical Utility of β-Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms

Florbetaben PET has potential as an adjunctive tool in the diagnosis of PLWH with cognitive impairment, increasing diagnostic certainty and optimizing management.

Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database

Semi-quantitative amyloid PET appears more powerful than CSF markers for AD grading and MCI prognosis in terms of cognitive decline and AD conversion.

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

The DTA of the 18F-florbetaben PET scan for detecting people with MCI at time of performing the test who will clinically progress to ADD, other forms of dementia (non-ADD), or any form of dementia at follow-up is evaluated.

A Single Baseline Amyloid Positron Emission Tomography Could Be Sufficient for Predicting Alzheimer’s Disease Conversion in Mild Cognitive Impairment

A single baseline amyloid PET could be sufficient in the prediction of AD conversion in MCI, with Cox proportional hazard model analysis and receiver operating characteristic (ROC) curve analysis showing significant associations with increased risk of conversion to AD.

Beta-amyloid imaging with florbetaben

Evidence shows that florbetaben is a valuable β-amyloid-targeting PET tracer in the clinic with great potential to serve as a biomarker supporting clinical AD diagnosis.

Advances in Brain Amyloid Imaging.

This review will compare available Aβ radiotracers, discuss approaches to quantification, as well as the clinical and research applications of Aβ PET, and identify Centiloid values that correlate well with neuropathologic findings and prognosis.

Impact of Tracer Retention Levels on Visual Analysis of Cerebral [18f]- Florbetaben pet Images.

Inter-rater agreement of visual analysis of amyloid PET images is high, and agreement between visual analysis and SUVr semi-quantitative analysis decreases in the range of 1.1 to 1.5 indicating lowest agreement for the group with intermediate amyloidal burden.


Compared with SWM and pons, which do not fulfil the RR requirements and have limited sensitivity to detect Aβ changes, cerebellar RRs are recommended for 18F-florbetaben PET because they allow earlier detection of Aβ accumulation.



Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline and convert to AD dementia at a higher rate than Aβ− subjects.

Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.

A measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings, as analyses of sensitivity and specificity of memory measures to detect high versus low Aβ scans suggested that word-list recall performed better when high sensitivity was preferred, whereas story recall performedbetter when high specificity was preferred.

Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias

18F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with 11C-Pittsburgh Compound B in a variety of neurodegenerative diseases.

Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease

FBB, while having a narrower dynamic range than PiB, clearly distinguished HC from AD patients, with a comparable effect size, and seems a suitable 18F radiotracer for imaging AD pathology in vivo.

Conversion of amyloid positive and negative MCI to AD over 3 years

PIB-positive subjects with mild cognitive impairment (MCI) are significantly more likely to convert to AD than PIB-negative patients, faster converters having higher PIB retention levels at baseline than slower converters.

Amyloid imaging and memory change for prediction of cognitive impairment

The way in which information on imaging-assessed Aβ burden and cognitive performance can be used jointly can be operationalized to improve prediction of clinical outcomes and enhance understanding of the role of Aβ deposition in cognitive impairment is operationalized.

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Comparison of levels of amyloid deposition to hippocampus volume (HV) and episodic memory (EM) in elderly subjects suggests that declining EM in older individuals may be caused by Abeta-induced hippocampus atrophy.